摘要
目的 探究贝伐珠单抗联合腹腔热灌注化疗(HIPEC)对腹腔转移晚期胃癌患者的治疗价值。方法 收集腹腔转移晚期胃癌患者64例,采取随机数表法分为试验组(n=32)与对照组(n=32)。两组患者均采用FOLFOX方案化疗,试验组在此基础上给予HIPEC,并于腹腔内注入贝伐珠单抗。治疗4个疗程后,比较两组患者的血清CEA、CA199、CA125等肿瘤标志物水平、KPS评分、治疗有效率、疾病控制率与治疗期间死亡率,同时分析贝伐珠单抗联合HIPEC对不同病理类型晚期胃癌的治疗效果。结果 与对照组相比,试验组患者的血清CEA、CA199与CA125等肿瘤标志物水平降低,KPS评分与治疗有效率、疾病控制率皆提高(P<0.05),而治疗期间死亡率的差异无统计学意义(P>0.05)。此外,贝伐珠单抗联合HIPEC在乳头状腺癌与黏液腺癌中的疗效显著(P<0.05),而对管状腺癌的效果不明显(P>0.05)。结论 在FOLFOX全身化疗的基础上,给予贝伐珠单抗联合HIPEC对腹腔转移晚期胃癌患者(乳头状腺癌与黏液腺癌)的疗效显著,具有一定的临床推广价值。
Objective To explore the value of bevacizumab combined with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the treatment of advanced gastric cancer with peritoneal metastasis. Methods 64 cases of abdominal metastasis of advanced gastric cancer were collected and randomly divided into the test group ( n =32) and the control group ( n =32).Patients of the 2 groups were given FOLFOX chemotherapy,and the test group was given HIPEC with intraperitoneal injection of bevacizumab.After 24 weeks of treatment,the level of serum CEA,CA199 and CA125,KPS scores,effective rate,disease control rate and mortality rate during the treatment were compared between the 2 groups,and the treatment efficiency in different pathologic types were also analyzed. Results Compared with the control group,the serum levels of tumor markers such as CEA,CA199 and CA125 in the test group were reduced,the KPS scores and the effective rate,the disease control rate were statistically increased ( P <0.05).There was no significant difference in mortality during treatment ( P >0.05).In addition,the efficacy of bevacizumab combined with HIPEC in papillary adenocarcinoma and mucous adenocarcinoma was significant ( P <0.05),but the effect on tubular adenocarcinoma was not obvious ( P >0.05). Conclusion On the basis of systemic chemotherapy,bevacizumab combined with HIPEC has significant curative effects in patients with advanced gastric cancer (papillary adenocarcinoma and mucous adenocarcinoma),and has potential value and broad prospects of clinical application.
作者
龙孝斌
刘晓飞
郭仪
LONG Xiaobin;LIU Xiaofei;GUO Yi(The First People's Hospital of Chenzhou,Chenzhou,423000)
出处
《实用癌症杂志》
2019年第6期978-981,共4页
The Practical Journal of Cancer
关键词
晚期胃癌
腹腔转移
腹腔热灌注化疗
贝伐珠单抗
Advanced gastric cancer
Peritoneal metastasis
Hyperthermic intraperitoneal peroperative chemotherapy
Bevacizumab
